CA2963383C - Method for the treatment of hypercholesterolemia - Google Patents

Method for the treatment of hypercholesterolemia Download PDF

Info

Publication number
CA2963383C
CA2963383C CA2963383A CA2963383A CA2963383C CA 2963383 C CA2963383 C CA 2963383C CA 2963383 A CA2963383 A CA 2963383A CA 2963383 A CA2963383 A CA 2963383A CA 2963383 C CA2963383 C CA 2963383C
Authority
CA
Canada
Prior art keywords
calebin
fat
density lipoproteins
mammals
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2963383A
Other languages
English (en)
French (fr)
Other versions
CA2963383A1 (en
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Anju Majeed
Sarang Bani
Anjali Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2963383A1 publication Critical patent/CA2963383A1/en
Application granted granted Critical
Publication of CA2963383C publication Critical patent/CA2963383C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2963383A 2014-04-23 2014-05-01 Method for the treatment of hypercholesterolemia Active CA2963383C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/259,404 2014-04-23
US14/259,404 US9668999B2 (en) 2014-04-23 2014-04-23 Method for the treatment of hypercholesterolemia
CA2850999A CA2850999C (en) 2014-04-23 2014-05-01 Method for the treatment of hypertriglyceridemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2850999A Division CA2850999C (en) 2014-04-23 2014-05-01 Method for the treatment of hypertriglyceridemia

Publications (2)

Publication Number Publication Date
CA2963383A1 CA2963383A1 (en) 2015-10-23
CA2963383C true CA2963383C (en) 2018-12-04

Family

ID=50828681

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2963383A Active CA2963383C (en) 2014-04-23 2014-05-01 Method for the treatment of hypercholesterolemia
CA2850999A Active CA2850999C (en) 2014-04-23 2014-05-01 Method for the treatment of hypertriglyceridemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2850999A Active CA2850999C (en) 2014-04-23 2014-05-01 Method for the treatment of hypertriglyceridemia

Country Status (11)

Country Link
US (2) US9668999B2 (https=)
EP (1) EP2937084B1 (https=)
JP (1) JP6263707B2 (https=)
KR (1) KR101647549B1 (https=)
AU (1) AU2014202312B2 (https=)
CA (2) CA2963383C (https=)
EA (1) EA027148B1 (https=)
MY (1) MY170067A (https=)
PH (1) PH12014000244A1 (https=)
PL (1) PL2937084T3 (https=)
TW (1) TWI622394B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503805XA (en) * 2015-04-19 2016-11-29 Sabinsa Corp Calebin A For Hepatic Steatosis
US9539232B1 (en) * 2016-08-04 2017-01-10 Muhammed Majeed Calebin A for osteoporosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060352C (zh) * 1996-02-08 2001-01-10 袁克兴 降脂药及其制备方法
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
WO2001030335A2 (en) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
US20020012733A1 (en) 2000-04-12 2002-01-31 The Procter & Gamble Company Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
JP4834824B2 (ja) * 2004-07-08 2011-12-14 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP2010018522A (ja) * 2007-03-23 2010-01-28 Hiroshima Univ アディポネクチン産生促進剤
JP5294165B2 (ja) * 2007-03-23 2013-09-18 ナガセケムテックス株式会社 アディポネクチン上昇剤
CN101301455A (zh) * 2008-07-01 2008-11-12 崔井朝 一种治疗高脂血症的中药复方姜黄固体分散体
JP2011063543A (ja) * 2009-09-17 2011-03-31 Kao Corp アディポネクチン増加剤
KR101702702B1 (ko) * 2011-01-10 2017-02-03 무하메드 마제에드 칼레빈 ａ의 항-비만 가능성

Also Published As

Publication number Publication date
US9668999B2 (en) 2017-06-06
HK1210590A1 (en) 2016-04-29
US20150306060A1 (en) 2015-10-29
JP2015209424A (ja) 2015-11-24
PL2937084T3 (pl) 2017-05-31
PH12014000244B1 (en) 2016-08-08
EA027148B1 (ru) 2017-06-30
AU2014202312B2 (en) 2018-02-22
TWI622394B (zh) 2018-05-01
EP2937084B1 (en) 2016-11-30
AU2014202312A1 (en) 2015-11-12
TW201540295A (zh) 2015-11-01
CA2850999C (en) 2018-04-03
US9610273B2 (en) 2017-04-04
KR101647549B1 (ko) 2016-08-10
CA2963383A1 (en) 2015-10-23
PH12014000244A1 (en) 2016-08-08
MY170067A (en) 2019-07-03
EP2937084A1 (en) 2015-10-28
CA2850999A1 (en) 2015-10-23
US20150306059A1 (en) 2015-10-29
KR20150122552A (ko) 2015-11-02
NZ624269A (en) 2014-12-24
JP6263707B2 (ja) 2018-01-24
EA201491545A1 (ru) 2015-10-30

Similar Documents

Publication Publication Date Title
CA2963383C (en) Method for the treatment of hypercholesterolemia
Kroll et al. Additional assessment of fecal corticosterone metabolites improves visual rating in the evaluation of stress responses of laboratory rats
Wang et al. Two kinds of traditional Chinese medicine prescriptions reduce thymic inflammation levels and improve humoral immunity of finishing pigs
Mirtha et al. The effect of foot exercise on diabetic patients with foot ulcer: An Evidence-based case report
CN1827618A (zh) 一类异喹啉衍生物、制备方法及用途
HK1210590B (en) Method for the treatment of hypercholesterolemia
NZ624269B (en) Method for the treatment of hypercholesterolemia
Moura et al. Pyroligneous extracts with therapeutic action: A technological prospect
JP2017176171A (ja) フコキサンチンをフコキサンチノール及びアマロウシアキサンチンａの形態で蓄積させた鶏卵、及び、それを用いた機能性加工食品、抗肥満材、除脂肪体重増加剤、並びに、鶏卵の産生方法
CA2986941C (en) New use of isoquinoline derivatives for diabetic wound healing
Halpern The Inflammation Revolution: A Natural Solution for Arthritis, Asthma & Other Inflammatory Disorders
JP2003265139A (ja) 癌細胞・エイズウイルスの生態防御免疫食品の製造方法
CN1857350A (zh) 一种增强免疫功能的药物或保健品及其制备方法
CN1524953A (zh) 抗衰老药物组合物及其制备方法
US20190224187A1 (en) New use of isoquinoline derivatives for wound healing
CN1596953A (zh) 治疗过敏性皮肤病的药物
CN104056252A (zh) 一种辅助抗辐射的组合物
Alimbuyao et al. Hypocholesterolemic and hypoglycemic effect of saccharum of officinale (sugar cane) peel crude extract in albino mice.
Bakker Veterinary care and welfare management in common marmosets
CN109172567A (zh) 马索亚内酯在制备预防和/或治疗自身免疫疾病药物或保健品方面的应用
Wedded et al. MARCH 15, Ir" 4 TREATMENTOF PULMONARY-TUBERCULOBIE. T
CN1108533A (zh) 治疗皮肤的增效组合物
TW201509420A (zh) 用於消耗體脂肪的組合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170404

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520